GlassScriptPhysician profile
Donald Vollmer
NPI 1184612921
$229,222.56
in general payments reported to CMS, 2019-2025
14 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $6,546 · 2021: $10K · 2022: $34K · 2023: $56K · 2024: $39K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Consulting Fee: $22K · Travel and Lodging: $12K · Food and Beverage: $4,832 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,805.00 |
| Consulting Fee | $22,395.00 |
| Travel and Lodging | $11,941.02 |
| Food and Beverage | $4,832.43 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $92,041.25 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $52,795.92 | 2019-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $31,440.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $14,322.29 | 2021-2023 | Lokelma |
| Sumitomo Pharma America, INC. | $13,260.12 | 2023-2024 | Gemtesa |
| Urovant Sciences INC | $9,088.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $7,566.39 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $6,846.31 | 2019-2022 | |
| Ucb, INC. | $793.26 | 2023-2024 | Briviact, Nayzilam |
| Sk Life Science, INC. | $573.31 | 2022-2024 | Xcopri |
| Avanir Pharmaceuticals, INC. | $288.84 | 2021-2022 | |
| Abbvie INC. | $125.00 | 2025 | |
| Neurelis, INC. | $48.28 | 2023 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.21 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Vollmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.